Latest Blogs

Sep 17, 2020
"The post-COVID world of medicine is a place of nuance at the new, tech-driven intersection of love and science," writes Dr. Douglas B. Flora of the virtual house call.
Sep 15, 2020
Dr. Deborah Mukherji and Dr. Sally Temraz conducted a survey which examined representation and barriers to women oncologists in the Middle East, and surfaced ideas for improving gender parity in the field.
Sep 10, 2020
My own recent hospitalization led me to reflect on the profound and essential role that nurses have had on my life. They have left an indelible imprint on my subconscious, and inspired the following poem.
Sep 09, 2020
"The COVID-19 pandemic’s impact is immediate for people who suffered from infection, but there is also an indirect impact on people who had to defer diagnosis and treatment plans, and the consequences of these delays will likely last for years," Dr. Dawood Findakly writes.
Subscribe to this column

Peter Paul Yu, MD, FASCO, FACP

Peter Paul Yu, MD, FACP, FASCO, is the physician-in-chief at Hartford HealthCare Cancer Institute. He is a past president of ASCO, past chair of the Breakthrough Co-Host Committee, and currently serves on the CancerLinQ Board of Governors, as an associate editor of JCO Clinical Cancer Informatics, and on the JCO Oncology Practice editorial board. Follow Dr. Yu on Twitter @YupOnc.

Disclosure.

Mar 11, 2012
In health care, we often find ourselves reacting to events rather than dictating them. Being cast in this undesirable position is often unavoidable when dealing with regulators and federal policy. However, the ability to foresee the need for change and thereby influence the direction of change is a...
Nov 20, 2011
This week the FDA decided to withdraw bevacizumab's indication for treatment of metastatic breast cancer. The earlier indication had been approved under FDA's accelerated approval process wherein final approval was conditional on the generation of confirmatory evidence based on clinical trials.
Nov 06, 2011
Let me start by mentioning 2 things I missed earlier about Day 1 of the ASCO HIT/EHRs Symposium.  In the session on Usability, Karen Bell, Chair of CCHIT, mentioned 3 areas where EHRs may impact malpractice risk; Communications, Documentation and Medical Errors. Each of these has the potential to...
Nov 06, 2011
The November 3rd edition of the NEJM features a Perspective article on drug shortages by Mandy Gatesman and Thomas J Smith (NEJM 365:18 page 163) that address many of the causative issues that underlie this growing national problem.  
Nov 04, 2011
Today was day 1 of the ASCO HIT/EHR Symposium, which covered a wide range of the ever changing HIT landscape.  Paul Tang, Vice Chair of the ONC HIT Policy Committee, and Chuck Friedman, former Chief Scientific Officer of ONC, now Director of Health Informatics at the U. Michigan School of Public...

Pages